Skip to content

Study · Randomized controlled trial · 1993

4 results

The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy.

Leather AT, Studd JW, Watson NR, Holland EF

Obstetrics and gynecology1 Jan 1993Cited by 49 (Europe PMC)

PMID8416441 (opens in a new tab)DOI10.1016/0020-7292(93)90299-c (opens in a new tab)PepBankPUB-08416441
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In women, goserelin plus placebo significantly reduced lumbar spine bone density compared with placebo plus placebo.

    In plain wordsIn women, goserelin plus placebo reduced lower spine bone density compared with placebo plus placebo.

    Peptide
    Goserelin
    Outcome
    DecreaseLumbar spine bone density versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo implant plus placebo ERT
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg every 4 weeks · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant loss of bone density at both the lumbar spine and proximal femur in the group receiving Zoladex plus placebo after 6 months compared with both pre-treatment values and with the group receiving placebo plus placebo.
    2 context sentences
    Summary · context
    In a double-blind, placebo-controlled study, 60 women aged 21-45 years were randomized to one of three treatment groups: placebo implant every 4 weeks plus placebo ERT tablets daily,
    Summary · context
    A dual x-ray bone density scan was performed before treatment and again after six treatment cycles.
  2. 02HumanRandomized controlled trialSafety outcome

    In women, goserelin plus placebo significantly reduced proximal femur bone density compared with placebo plus placebo.

    In plain wordsIn women, goserelin plus placebo reduced upper thigh bone density compared with placebo plus placebo.

    Peptide
    Goserelin
    Outcome
    DecreaseProximal femur bone density versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo implant plus placebo ERT
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg every 4 weeks · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant loss of bone density at both the lumbar spine and proximal femur in the group receiving Zoladex plus placebo after 6 months compared with both pre-treatment values and with the group receiving placebo plus placebo.
    2 context sentences
    Summary · context
    In a double-blind, placebo-controlled study, 60 women aged 21-45 years were randomized to one of three treatment groups: placebo implant every 4 weeks plus placebo ERT tablets daily,
    Summary · context
    A dual x-ray bone density scan was performed before treatment and again after six treatment cycles.
  3. 03HumanNon-randomized trialSafety outcome

    In women, goserelin plus placebo significantly reduced lumbar spine bone density versus pretreatment values.

    In plain wordsIn women, goserelin plus placebo reduced lower spine bone density compared with pretreatment values.

    Peptide
    Goserelin
    Outcome
    DecreaseLumbar spine bone density versus baseline
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg every 4 weeks · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant loss of bone density at both the lumbar spine and proximal femur in the group receiving Zoladex plus placebo after 6 months compared with both pre-treatment values and with the group receiving placebo plus placebo.
    2 context sentences
    Summary · context
    In a double-blind, placebo-controlled study, 60 women aged 21-45 years were randomized to one of three treatment groups: placebo implant every 4 weeks plus placebo ERT tablets daily,
    Summary · context
    A dual x-ray bone density scan was performed before treatment and again after six treatment cycles.
  4. 04HumanNon-randomized trialSafety outcome

    In women, goserelin plus placebo significantly reduced proximal femur bone density versus pretreatment values.

    In plain wordsIn women, goserelin plus placebo reduced upper thigh bone density compared with pretreatment values.

    Peptide
    Goserelin
    Outcome
    DecreaseProximal femur bone density versus baseline
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg every 4 weeks · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant loss of bone density at both the lumbar spine and proximal femur in the group receiving Zoladex plus placebo after 6 months compared with both pre-treatment values and with the group receiving placebo plus placebo.
    2 context sentences
    Summary · context
    In a double-blind, placebo-controlled study, 60 women aged 21-45 years were randomized to one of three treatment groups: placebo implant every 4 weeks plus placebo ERT tablets daily,
    Summary · context
    A dual x-ray bone density scan was performed before treatment and again after six treatment cycles.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.